FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
Approval is based on positive data from the Phase 3 ECHELON-3 trial
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
Ipratropium Bromide Nasal Solution is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis
Hikal Limited announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru
Branded formulation business continues to perform well across domestic and export markets
Cancer cases in India estimated to reach 1.57 million in 2025
It will bring together renowned global experts in the field to discuss groundbreaking advances in biomaterials and their clinical applications
Subscribe To Our Newsletter & Stay Updated